Childhood vaccinations and risk of asthma
Frank DeStefanoDavid X GuPiotr KramarzBenedict I. TrumanMichael F. IademarcoJohn P. MulloolyLisa A. JacksonRobert L. DavisSteven BlackHenry R. ShinefieldS. Michael MarcyJoel I. WardRobert T. Chen
109
Citation
40
Reference
10
Related Paper
Citation Trend
Abstract:
A few previous studies have suggested that childhood vaccines, particularly whole cell pertussis vaccine, may increase the risk of asthma. We evaluated the suggested association between childhood vaccinations and risk of asthma.Cohort study involving 167,240 children who were enrolled in 4 large health maintenance organizations during 1991 to 1997, with follow-up from birth until at least 18 months to a maximum of 6 years of age. Vaccinations were ascertained through computerized immunization tracking systems, and onset of asthma was identified through computerized data on medical care encounters and medication dispensings.In the study 18,407 children (11.0%) developed asthma, with a median age at onset of 11 months. The relative risks (95% confidence intervals) of asthma were: 0.92 (0.83 to 1.02) for diphtheria, tetanus and whole cell pertussis vaccine; 1.09 (0.9 to 1.23) for oral polio vaccine; 0.97 (0.91 to 1.04) for measles, mumps and rubella (MMR) vaccine; 1.18 (1.02 to 1.36) for Haemophilus influenzae type b (Hib); and 1.20 (1.13 to 1.27) for hepatitis B vaccine. The Hib result was not consistent across health maintenance organizations. In a subanalysis restricted to children who had at least 2 medical care encounters during their first year, the relative risks decreased to 1.07 (0.71 to 1.60) for Hib and 1.09 (0.88 to 1.34) for hepatitis B vaccine.There is no association between diphtheria, tetanus and whole cell pertussis vaccine, oral polio vaccine or measles, mumps and rubella vaccine and the risk of asthma. The weak associations for Hib and hepatitis B vaccines seem to be at least partially accounted for by health care utilization or information bias.Keywords:
Hepatitis A vaccine
Hepatitis B vaccine
Pertussis vaccine
MMR vaccine
Measles-Mumps-Rubella Vaccine
The purpose of this work was to assess the association between media coverage of the MMR-autism controversy and MMR immunization in the United States.The public-use files of the National Immunization Survey were used to estimate annual MMR coverage from 1995 to 2004. The primary outcome was selective measles-mumps-rubella nonreceipt, that is, those children who received all childhood immunizations except MMR. Media coverage was measured by using LexisNexis, a comprehensive database of national and local news media. Factors associated with MMR nonreceipt were identified by using a logistic regression model.Selective MMR nonreceipt, occurring in as few as 0.77% of children in the 1995 cohort, rose to 2.1% in the 2000 National Immunization Survey. Children included in the 2000 National Immunization Survey were born when the putative link between MMR and autism surfaced in the medical literature but before any significant media attention occurred. Selective nonreceipt was more prevalent in private practices and unrelated to family characteristics. MMR nonreceipt returned to baseline before sustained media coverage of the MMR-autism story began.There was a significant increase in selective MMR nonreceipt that was temporally associated with the publication of the original scientific literature, suggesting a link between MMR and autism, which preceded media coverage of the MMR-autism controversy. This finding suggests a limited influence of mainstream media on MMR immunization in the United States.
MMR vaccine
Measles-Mumps-Rubella Vaccine
Rubella vaccine
Cite
Citations (163)
M-M-RTM II (MMRII; Merck & Co) is currently the only measles-mumps-rubella (MMR) vaccine licensed in the United States. Another licensed vaccine would reinforce MMR supply. This study assessed the immunogenicity of a candidate vaccine ( PriorixTM , GlaxoSmithKline Vaccines [MMR-RIT]) when used as a first dose among eligible children in the United States. In this exploratory Phase-2, multicenter, observer-blind study, 1220 healthy subjects aged 12–15 months were randomized (3:3:3:3) and received 1 dose of 1 of 3 MMR-RIT lots with differing mumps virus titers (MMR-RIT-1 [4.8 log 10 ]; MMR-RIT-2 [4.1 log 10 ]; MMR-RIT-3 [3.7 log 10 ] CCID50) or MMRII co-administered with hepatitis A vaccine (HAV), varicella vaccine (VAR) and 7-valent pneumococcal conjugate vaccine (PCV7). Immune response to measles, mumps, and rubella viruses was evaluated at Day 42 post-vaccination. Incidence of solicited injection site, general, and serious adverse events was assessed. Seroresponse rates for MMR vaccine viral components in MMR-RIT lots were 98.3–99.2% (measles), 89.7–90.7% (mumps), and 97.5–98.8% (rubella), and for MMRII were 99.6%, 91.1%, and 100%, respectively. Immune responses to HAV, VAR, and PCV7 were similar when co-administered with any of the 3 MMR-RIT lots or MMRII. There were no apparent differences in solicited or serious adverse events among the 4 groups. Immune responses were above threshold levels for projected protection against the 3 viruses from MMR-RIT lots with differing mumps virus titers. MMR-RIT had an acceptable safety profile when co-administered with HAV, VAR, and PCV7. NCT00861744; etrack ; 111870
MMR vaccine
Measles-Mumps-Rubella Vaccine
Hepatitis A vaccine
Rubella vaccine
Cite
Citations (19)
MMR vaccine is a controversial topic of public debate. The controversies include such issues as autism, adjuvants or ethical questions related to the culturing of the rubella virus on human cell lines.The objective was to characterise the public debate on MMR vaccination on the Polish Internet between January 2018 and June 2020.Quantitative and qualitative analysis of Polish-language online content between 1 January 2018 and 30 June 2020 related to MMR vaccination. The quantitative analysis comprised all available mentions of MMR vaccination in postings (n=14,632), while qualitative analysis relied on a systematic sample of 819 mentions.Quantitative study: 79.6% of MMR vaccine-related postings were published on Facebook, 6.9% on Twitter, and the remaining 14.6% appeared on other websites. There were two surges in posting count in November 2018 and March 2019. Qualitative study: 48% of postings expressed anti-vaccination sentiment, 33% were pro-vaccination and 19% were neutral.The social media play a significant role in the dissemination of untrue medical claims regarding MMR vaccination. A substantial part of the discussion about MMR vaccination in Poland takes place on Facebook. Despite the general availability of research results stating the absence of a link between autism and vaccination, this is an ongoing most frequent topics in the MMR debate. At the same time, more postings on that topic expressed pro-vaccination rather than anti-vaccination sentiment.
MMR vaccine
Measles-Mumps-Rubella Vaccine
Rubella vaccine
Cite
Citations (2)
OBJECTIVE: To evaluate the proposed link between the administration of the measles, mumps, and rubella (MMR) vaccine and the development of autism. DATA SOURCES: A literature search utilizing MEDLINE (1966–November 2003), with the key terms measles, mumps, rubella, and autism, was conducted. Review of the references listed in the articles identified was also performed. DATA SYNTHESIS: Ten articles that specifically evaluated the possible relationship between the MMR vaccine and autism were identified. Review articles, commentaries, and evaluations of a link between gastrointestinal symptoms in autistic children and MMR immunization were excluded. CONCLUSIONS: Based upon the current literature, it appears that there is no relationship between MMR vaccination and the development of autism.
MMR vaccine
Measles-Mumps-Rubella Vaccine
Cite
Citations (23)
MMR vaccine
Measles-Mumps-Rubella Vaccine
Rubella vaccine
Mumps vaccine
Cite
Citations (2)
MMR vaccine
Measles-Mumps-Rubella Vaccine
Receipt
Cite
Citations (116)
MMR vaccine
Measles-Mumps-Rubella Vaccine
Mumps vaccine
Rubella vaccine
Notifiable disease
Cite
Citations (14)
The introduction of vaccination programs against measles, mumps, and rubella (MMR) led to significant global reduction in morbidity and mortality from these diseases. The currently recommended MMR vaccination schedule in the United States of America comprises 2 vaccine doses typically administered at 12–15 months and 4–6 years, respectively. Considering recent outbreaks in the USA, catch-up vaccination with an additional dose of MMR vaccine could contribute to outbreak control and community protection. This phase III, observer-blind, randomized controlled trial (NCT02058563) assessed the immunogenicity and safety of a dose of the MMR-RIT vaccine (Priorix, GSK) compared to MMR II vaccine (control; M-M-R II, Merck&Co Inc.) in ≥7-year-olds who had received ≥1 previous dose of MMR vaccine. We assessed anti-measles, anti-mumps, and anti-rubella antibody geometric mean concentrations (GMCs; primary endpoint) and seroresponse rates (SRRs) at day 42 post-vaccination. Solicited, unsolicited, and serious adverse events (AEs) were recorded. The according-to-protocol cohort for immunogenicity included 869 participants (MMR-RIT: N = 433; MMR II: N = 436). We observed anti-measles, anti-mumps, and anti-rubella antibody GMCs of 1790.2 mIU/mL, 113.5 EU/mL, and 76.1 IU/mL, respectively, and SRRs of 98.8%, 98.4%, and 99.5%, respectively, after a dose of MMR-RIT; non-inferiority compared to MMR II was demonstrated. Both vaccines showed comparable reactogenicity profiles; the most common solicited AEs were injection site redness and pain, and fever (MMR-RIT: 12.2%, 11.8%, and 3.0%; MMR II: 11.7%, 11.5%, and 5.2%, respectively). The dose of MMR-RIT induced robust immune responses that were not inferior to those of MMR II, and was well tolerated.
MMR vaccine
Reactogenicity
Measles-Mumps-Rubella Vaccine
Rubella vaccine
Cite
Citations (37)
Objective To evaluate the effectiveness of mass vaccination campaign of hepatitis A vaccine(Hep A)and Measles-Mumps-Rubella live attenuated vaccine(MMR) vaccine in children in stricken regions of 4.20 Lushan earthquake in Sichuan province. Methods As the requirements of Sichuan Provincial Health Bureau, the mass campaign was implemented in Lushan county, Baoxing county and the victim settlement localities of other 6 counties during May 6th to12th, 2013. Hep A and MMR were vaccinated, which targeted children aged from 18 months to 14 years and children aged from 8 months to 14 years, respectively. The vaccination rates were evaluated through reports and on-site rapid review of earthquake regions. Results As of May 16th, 2013, 38 988 doses of Hepatitis A vaccine and 38 696 doses of MMR vaccine were vaccinated in 8 counties of Ya'an. Based on reports, the vaccination rates of Hep A and MMR vaccine of Ya'an were 99.01% and 98.87%, respectively. Based on reviews, vaccination rates of Hep A and MMR vaccine of Lushan and Baoxing were 97.40% and 97.06%, respectively. Conclusion Mass vaccination campaign of Hep A and MMR in children in stricken regions of 4.20 Lushan earthquake in Sichuan province yields expected results. The mass campaign is wellorganized and implemented effectively, and the coverage matches the requirements. Timely decision, assistance from associated prefectures and the establishment of Childhood Immunization Information System play an important role in the campaign.
MMR vaccine
Hepatitis A vaccine
Measles-Mumps-Rubella Vaccine
Rubella vaccine
Mass vaccination
Cite
Citations (0)